Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

被引：0

作者：

Siegel, David S. ^{[1
,2
]}

Schiller, Gary J. ^{[3
]}

Samaras, Christy J. ^{[4
]}

Sebag, Michael ^{[5
]}

Berdeja, Jesus G. ^{[6
]}

Ganguly, Siddhartha ^{[7
]}

Matous, Jeffrey V. ^{[8
]}

Song, Kevin ^{[9
]}

Seet, Christopher S. ^{[10
]}

Talamo, Giampaolo ^{[11
]}

Acosta-Rivera, Mirelis ^{[12
]}

Bar, Michael ^{[13
]}

Quick, Donald P. ^{[14
]}

Anz, Bertrand ^{[15
]}

Fonseca, Gustavo ^{[16
]}

Reece, Donna ^{[17
]}

Agarwal, Amit ^{[18
]}

Chung, Weiyuan ^{[18
]}

Zafar, Faiza ^{[18
]}

Bahlis, Nizar ^{[19
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Myeloma Div, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[3] UCLA, David Geffen Sch Med, Los Angeles, CA USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[5] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Univ Kansas, Ctr Canc, Fairway, KS USA

[8] Colorado Blood Canc Inst, Denver, CO USA

[9] Vancouver Gen Hosp, Vancouver, BC, Canada

[10] UCLA, Med Ctr, Los Angeles, CA USA

[11] Penn State Hershey Canc Inst, Hershey, PA USA

[12] Fdn Invest, San Juan, PR USA

[13] Stamford Hosp, Stamford, CT USA

[14] Joe Arrington Canc Res Treatment Ctr, Lubbock, TX USA

[15] Tennessee Oncol, Chattanooga, TN USA

[16] Florida Canc Specialists, St Petersburg, FL USA

[17] Princess Margaret Canc Ctr, Toronto, ON, Canada

[18] Celgene Corp, Summit, NJ USA

[19] Univ Calgary, Calgary, AB, Canada

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111920

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3271

引用

页数：4

共 50 条

[1] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
Siegel, David S.
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Samaras, Christy
Malek, Ehsan
Talamo, Giampaolo
Seet, Christopher S.
Mouro, Jorge
Pierceall, William E.
Zafar, Faiza
Chung, Weiyuan
Srinivasan, Shankar
Agarwal, Amit
Bahlis, Nizar J.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
[2] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
Siegel, David Samuel DiCapua
Schiller, Gary J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo
Reece, Donna Ellen
Zafar, Faiza
Chung, Weiyuan
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
Matsue, Kosei
Sunami, Kazutaka
Matsumoto, Morio
Kuroda, Junya
Sugiura, Isamu
Iwasaki, Hiromi
Chung, Weiyuan
Kuwayama, Shigeki
Nishio, Mitsufumi
Lee, Kim
Iida, Shinsuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 122 - 130
[4] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
Kosei Matsue
Kazutaka Sunami
Morio Matsumoto
Junya Kuroda
Isamu Sugiura
Hiromi Iwasaki
Weiyuan Chung
Shigeki Kuwayama
Mitsufumi Nishio
Kim Lee
Shinsuke Iida
International Journal of Hematology, 2022, 116 : 122 - 130
[5] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen J.
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Raymond
Wang, Jianping
Nottage, Kerri
Chiu, Christopher
Khokhar, Nushmia Z.
Ahmadi, Tahamtan
Lonial, Sagar
BLOOD, 2017, 130 (08) : 974 - 981
[6] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel
Gary J. Schiller
Christy Samaras
Michael Sebag
Jesus Berdeja
Siddhartha Ganguly
Jeffrey Matous
Kevin Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald Quick
Bertrand Anz
Gustavo Fonseca
Donna Reece
William E. Pierceall
Weiyuan Chung
Faiza Zafar
Amit Agarwal
Nizar J. Bahlis
Leukemia, 2020, 34 : 3286 - 3297
[7] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Siegel, David S.
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Pierceall, William E.
Chung, Weiyuan
Zafar, Faiza
Agarwal, Amit
Bahlis, Nizar J.
LEUKEMIA, 2020, 34 (12) : 3286 - 3297
[8] A health-related quality-of-life (HRQoL) analysis of pomalidomide plus low-dose dexamethasone plus daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
Reece, Donna Ellen
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo A.
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David Samuel DiCapua
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Health-Related Quality of Life With Pomalidomide plus Dexamethasone plus Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients
Reece, Donna
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E277 - E278
[10] Pomalidomide plus Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety
Siegel, David S.
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Reu, Fred J.
Malek, Ehsan
Mouro, Jorge L.
Chung, Weiyuan
Srinivasan, Shankar
Qian, Max
Rizvi, Syed
Thakurta, Anjan
Bahlis, Nizar J.
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →